NAMSR News: Merz Medical set to acquire Ulthera, Inc
Merz and Ulthera, Inc announced today that they have entered a definitive merger contract, pursuant to which Merz will obtain the global DME company Ulthera.
"This acquisition represents an important strategic milestone for Merz," said Philip Burchard, CEO of Merz Pharma Group, which has associates in 18 different countries around the world. "We have a vision to be the most innovative company in aesthetics, and expanding into the rapidly growing field of energy devices will position us for long-term success in this area. The addition of Ulthera's energy device technology complements and expands our global presence in the aesthetics space."
Founded in 2004, Ulthera is among leaders in non-surgical lifting and tightening treatments. By therapeutic ultrasound technology, the Ulthera® System is the first and only ultrasound platform device to receive FDA clearance for lifting skin on the eyebrow, the neck and under the chin. Ulthera assumes sales greater than $100 million in 2014.
"The aesthetic lift indication differentiates Ulthera from every other energy device available in the market today," said Bill Humphries, President and CEO of Merz North America, Inc. "It is truly innovative technology, and we expect to leverage our in-house clinical expertise to develop further aesthetic and medical applications and bring them to the international marketplace."
Merz and Ulthera have a joint mission: bring innovations to a marketplace that can meet the needs of physicians while improving the well-being of their patients. This mutual long-term vision offers a solid foundation for the joint companies. "Joining with a like-minded, growing global healthcare company is a major milestone in the life of our company," said Ulthera CEO Matt Likens. "Through our collaboration with Merz, we hope to introduce the Ulthera® System to new customers and markets around the world."
"Building on this important new partnership, Merz will continue to seek innovative M&A and licensing opportunities on a global scale," said Hans-Jörg Bergler, Head of Corporate Development for Merz Pharma Group.
The deal has been approved by both of the companies’ boards and is center to customary closing conditions, as well as the expiration or termination of the associated waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The contract is expected to close in the third quarter of 2014.
CANDIDATES WHO WANT TO BREAK INTO MEDICAL SALES:
RMSR® Medical Sales Certification offered by the National Association of Medical Sales Representatives is designed for entry level medical device sales reps. The course covers a wide array of topics pertaining to industry knowledge that candidates need to acquire before applying to medical sales positions.
The course and training helps to develop the industry skills, maximizing the candidates’ potential and goals, as well as making them feel valued and stimulated in their role when communicating with members of the medical community. By an applicant acquiring medical sales training and a RMSR Certification, it puts him/her in a position of strength and qualifies them for medical sales jobs. Medical knowledge is key in this industry and when communicating with doctors, surgeons, and nurses etc. It is extremely important for representatives to use key terminology pertaining to the medical product he/she will be promoting. The only way to succeed in this industry is to garner actual sales. Doctors and Surgeons will not acknowledge a Sales Rep who is not proficient in essential medical terminology, knowledgeable of medical devices/equipment and the anatomy. For those lacking a solid sales background the RMSR course covers knowledge of medical selling techniques and regulation such as Effective Territory Management, Effective Networking, Medical Sales Ethical & Regulatory Guidelines and more.
The National Association of Medical Sales Representative™
For more information on the NAMSR or the RMSR certification visit www.medicalsalescareer.com or call 800-313-9198